IRIS
GIORGIO, Carmine
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.364
AS - Asia 3.624
EU - Europa 3.336
SA - Sud America 479
AF - Africa 244
Continente sconosciuto - Info sul continente non disponibili 4
Totale 13.051
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.246
SG - Singapore 1.215
CN - Cina 1.009
IT - Italia 970
VN - Vietnam 635
FI - Finlandia 446
IE - Irlanda 427
DE - Germania 411
BR - Brasile 381
SE - Svezia 345
HK - Hong Kong 233
FR - Francia 163
ZA - Sudafrica 154
IN - India 146
GB - Regno Unito 117
TR - Turchia 94
NL - Olanda 93
UA - Ucraina 78
RU - Federazione Russa 75
CA - Canada 57
BE - Belgio 52
BD - Bangladesh 43
CI - Costa d'Avorio 43
AR - Argentina 41
MX - Messico 38
JP - Giappone 32
ID - Indonesia 31
AT - Austria 28
IQ - Iraq 26
KR - Corea 25
CZ - Repubblica Ceca 21
ES - Italia 21
PK - Pakistan 20
PL - Polonia 20
PH - Filippine 19
TH - Thailandia 19
EC - Ecuador 14
JO - Giordania 13
RO - Romania 12
VE - Venezuela 12
LT - Lituania 11
SA - Arabia Saudita 11
CO - Colombia 9
EG - Egitto 9
MA - Marocco 8
AL - Albania 7
CH - Svizzera 7
HU - Ungheria 7
TN - Tunisia 7
UZ - Uzbekistan 7
CL - Cile 6
KE - Kenya 6
KG - Kirghizistan 6
MY - Malesia 6
PY - Paraguay 6
BO - Bolivia 5
ET - Etiopia 5
HN - Honduras 5
TW - Taiwan 5
JM - Giamaica 4
PA - Panama 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
DZ - Algeria 3
EU - Europa 3
HR - Croazia 3
NP - Nepal 3
OM - Oman 3
PS - Palestinian Territory 3
RS - Serbia 3
SN - Senegal 3
AZ - Azerbaigian 2
BG - Bulgaria 2
CR - Costa Rica 2
IL - Israele 2
IR - Iran 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
NO - Norvegia 2
PT - Portogallo 2
QA - Qatar 2
SC - Seychelles 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
CG - Congo 1
CM - Camerun 1
GA - Gabon 1
GF - Guiana Francese 1
GR - Grecia 1
GT - Guatemala 1
Totale 13.042
Salva come PNG Salva come JPEG
Città #
Dallas 1.620
Singapore 663
Ashburn 489
Dublin 427
Chandler 393
Parma 347
San Jose 297
Ann Arbor 282
Santa Clara 264
Beijing 222
Hong Kong 214
Ho Chi Minh City 194
Munich 179
Boardman 160
Johannesburg 149
Dearborn 143
Hanoi 143
Shanghai 96
Helsinki 95
Los Angeles 88
New York 88
Jacksonville 87
Nanjing 76
Hefei 75
Izmir 71
Lauterbourg 68
Princeton 60
Bremen 59
Wilmington 55
Bologna 47
Abidjan 43
Brussels 41
São Paulo 41
Chicago 40
Council Bluffs 38
Columbus 37
Milan 31
Shenyang 31
Frankfurt am Main 30
San Mateo 30
Haiphong 29
London 29
Buffalo 28
Moscow 28
Bangalore 27
Guangzhou 27
Turku 27
Kunming 26
Da Nang 23
Tokyo 22
Brescia 21
Modena 21
Toronto 21
Jakarta 20
Vienna 20
Jinan 19
Lubbock 19
Orem 19
Seoul 19
Nanchang 18
Nuremberg 18
Seattle 18
Des Moines 17
Düsseldorf 17
Fremont 17
Hebei 17
The Dalles 17
Montreal 16
Rio de Janeiro 16
Changsha 15
Grafing 15
Reggio Emilia 15
Houston 14
Jiaxing 14
Mexico City 14
Woodbridge 14
Tianjin 13
Belo Horizonte 12
Brooklyn 12
Dalmine 12
Hangzhou 12
Amman 11
Ankara 11
Boston 11
Brno 11
Chennai 11
Münster 11
Piacenza 11
Warsaw 11
Amsterdam 10
Bangkok 10
Bengaluru 10
Biên Hòa 10
Denver 10
Phoenix 10
Poplar 10
Rome 10
Stockholm 10
Atlanta 9
Concesio 9
Totale 8.487
Salva come PNG Salva come JPEG
Nome #
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.683
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 298
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 250
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 240
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 239
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 231
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 215
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 214
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 202
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 201
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 200
Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation 198
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 197
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 196
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 191
Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. 190
Multi-Target CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach 184
Impact of S1P mimetics on mesenteric ischemia/reperfusion injury 182
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 181
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 176
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 176
Enhanced photosensitizing properties of protein bound curcumin 175
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 172
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 171
Hypericin - apomyoglobin an enhanced photosensitizer complex for the treatment of tumor cells 170
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 166
Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis 164
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 162
Perturbation of The EphA2-EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites 161
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 161
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 161
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 161
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 160
Botanicals used as food supplements interfering with EphA2-ephrinA1 system: a screening study 156
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 156
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 155
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 153
Discovery of small-molecule targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases 152
Structure activity relationship of new EphA2 ligands 149
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 149
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 148
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 148
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 148
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 146
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 145
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 144
Discovery of natural extracts interfering with EphA2-ephrinA1 system 142
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 142
Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation. 141
Benzofuran-2-Carboxamide Derivatives as Immunomodulatory Agents Blocking the CCL20-Induced Chemotaxis and Colon Cancer Growth 140
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 140
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 139
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 138
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present) 134
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 133
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 132
Antinflammatory properties of novel 5-amino[1,2,4]-triazolo[4,3-a][1,8]naphthyridines-caroboxamides derivatives 124
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 123
Target-hopping: a useful approach to identify novel Eph receptor antagonists 122
Lithocholic acid competitively inhibits EphA2-ephrinA1 binding: pharmacological and structural considerations. 121
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 118
Recombinant Alpha-1 Antitrypsin as Dry Powder for Pulmonary Administration: A Formulative Proof of Concept 117
Investigation on the anti-inflammatory properties of Ocotea quixos Lam. essential oil. 115
Ocotea quixos Lam. essential oil: In vitro and in vivo investigation on its anti-inflammatory properties. 112
Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. 111
Therapeutic perspectives of Eph–ephrin system modulation 109
Drug discovery: In silico dry data can bypass biological wet data? 105
Su1816–Protection by Ccr6 Blockade in a Murine Model of Crohn’s Disease 104
Effects of CCL20/CCR6 modulators in a T cell adoptive transfer model of colitis 101
Ephrin or not? Six tough questions on Eph targeting 100
UNIPR1331: SMALL EPH/EPHRIN ANTAGONIST BENEFICIAL IN INTESTINAL INFLAMMATION BY INTERFERING WITH TYPE-B SIGNALLING 99
In vitro and in vivo efficacy of an orally bioavailable antagonist of Eph-ephrin system in tumor angiogenesis and growth 89
Targeting Eph/ephrin system in cancer therapy 84
Studies on the antiplatelet and antithrombotic profile of anti-inflammatory coumarin derivatives 76
Protection by Eph/ephrin antagonists against TNBS-induced colitis: effects of the route of administration 69
Dual targeting of EphAs and KDR axis hampers VEGF-induced angiogenesis and glioma stem cell replication 47
The rare bile acid isoallolithocholic acid (IALCA) is an EphA2 antagonist sparing FXR and TGR5 receptors 28
Totale 13.232
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.930
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.930
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202197 0 0 0 0 0 0 0 0 0 36 33 28
2021/2022539 24 23 27 108 36 27 45 44 36 40 18 111
2022/20231.650 161 172 77 133 185 175 42 89 505 27 56 28
2023/2024693 44 41 36 35 47 129 67 53 27 47 75 92
2024/20252.333 98 115 132 117 251 243 176 149 296 200 204 352
2025/20265.782 436 714 1.592 426 642 282 484 180 672 354 0 0
Totale 13.232